source
- Analysts Question Biogen's Lupus Drug Litifilimab Ahead of Key Phase 3 ReadoutsAnalysts pressed Biogen CEO Chris Viehbacher during a recent call, focusing on the company's late‑stage pipeline. The discussion centered on litifilimab, Biogen’s experimental lupus therapy, with…
- Chinese biotech BioGeometry secures over $100 million Series A for AI-driven protein designBioGeometry, a four-year-old biotech startup based in Beijing, announced it has closed a Series A financing round of more than $100 million. The capital will be used to expand its artificial-intel…